BTIG Reaffirms Buy Rating on iRhythm Holdings, Inc.
BTIG analyst Marie Thibault reiterates a buy rating on iRhythm with a $185 price target.
Key Points
- BTIG analyst Marie Thibault reiterated a buy rating on iRhythm Holdings, Inc. with a $185 price target on June 10, 2026.
- Shares of NasdaqGS:IRTC traded near $113.65, with a market cap of about $3.73 billion and a forward P/E ratio of 108.1.
- Insider transactions included both buying and selling, with recent buys by executives like CEO Quentin Blackford.
On June 10, 2026, BTIG analyst Marie Thibault reiterated a buy rating for iRhythm Holdings, Inc. (NasdaqGS: IRTC), maintaining a price target of $185. This comes as shares of the digital healthcare company traded around $113.65.
Analysts Set New Price Targets
Thibault's reiteration of a buy rating at a target of $185 highlights continued confidence in iRhythm. Just days earlier, Canaccord Genuity maintained its buy rating with a $152 target, and B of A Securities echoed a similar sentiment with a $180 target. Citigroup, JP Morgan, and Wells Fargo have all recently maintained buy ratings, underscoring a strong consensus among analysts.
Other Institutional Activity in iRhythm Holdings
Institutional activity has been bustling around iRhythm. Tudor Investment Corp Et Al added a substantial 20 million shares, bringing its total to the same number, valued at about $21.97 million. BlackRock, Inc. slightly trimmed its position by 72,484 shares, ending with over 2.74 million shares worth approximately $323.55 million. Meanwhile, RTW Investments, LP increased its stake by 486,510 shares, now holding around 1.67 million shares valued at $196.92 million.
iRhythm Holdings Stock Snapshot
Shares of iRhythm Holdings, Inc. are currently trading near $113.65. The company, with a market cap of approximately $3.73 billion, has a forward P/E ratio of 108.1, indicating high expected growth. Its stock has fluctuated between $101.75 and $212 over the past 52 weeks. The company's 50-day moving average is $117.21, while the 200-day moving average stands at $151.76.
Insider Buying and Selling at iRhythm Holdings, Inc.
Recent insider activity at iRhythm included both buying and selling. On June 2, 2026, Chief Accounting Officer Marc Wade Rosenbaum sold 729 shares at an average price of $108.19. EVP and Chief Risk Officer Sumi Shrishrimal also sold 1,716 shares at the same price. On May 29, several executives, including CEO Quentin Blackford, purchased shares at $96.82, indicating some internal confidence in the stock's future.
About iRhythm Holdings, Inc.
Based in San Francisco, iRhythm Holdings, Inc. is a digital healthcare company specializing in device-based technology for ambulatory cardiac monitoring. Its flagship Zio services help diagnose arrhythmias through long-term and short-term monitoring. The company is led by CEO Quentin Blackford and employs about 2,400 people.
Bottom Line
BTIG's reiterated buy rating and the $185 price target for iRhythm Holdings, Inc. reflect continued analyst confidence in the company. With its shares trading around $113.65, iRhythm remains a focal point for institutional investors and insiders alike. Remember, 13F filings reflect past holdings and may not indicate current positions.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.